Lupus Nephritis: Natural History, Prognosis and Treatment

JAMES E. BALOW
{"title":"Lupus Nephritis: Natural History, Prognosis and Treatment","authors":"JAMES E. BALOW","doi":"10.1016/S0260-4639(22)00081-0","DOIUrl":null,"url":null,"abstract":"<div><p>Lupus nephritis is composed of a continuum of clinical and morphological features. The World Health Organization classification delineates categories of lupus nephritis which have some unique characteristics. However, its utility for assessing prognosis and indications for treatment can be enhanced by supplementary description of activity and chronicity features of the renal pathology.</p><p>The prognosis of all forms of lupus nephritis has improved over the past several decades as a result of improved ancillary medical therapies and more effective immunosuppressive regimens. Some patients with active lupus nephritis may respond dramatically and completely to high-dose prednisone. More commonly, such therapy achieves incomplete responses and disposes patients to a high probability of progressive renal scarring and a substantial risk of end-stage renal failure. Conventional cytotoxic drug therapy with azathioprine or cyclophosphamide reduces the likelihood of unfavourable renal outcomes, but this advantage is offset by a number of potentially serious side-effects. Intermittent pulse cyclophosphamide treatment produces the lowest risk of renal failure and appears to have a substantially reduced rate of toxicity.</p></div>","PeriodicalId":100282,"journal":{"name":"Clinics in Immunology and Allergy","volume":"6 2","pages":"Pages 353-366"},"PeriodicalIF":0.0000,"publicationDate":"1986-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinics in Immunology and Allergy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0260463922000810","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Lupus nephritis is composed of a continuum of clinical and morphological features. The World Health Organization classification delineates categories of lupus nephritis which have some unique characteristics. However, its utility for assessing prognosis and indications for treatment can be enhanced by supplementary description of activity and chronicity features of the renal pathology.

The prognosis of all forms of lupus nephritis has improved over the past several decades as a result of improved ancillary medical therapies and more effective immunosuppressive regimens. Some patients with active lupus nephritis may respond dramatically and completely to high-dose prednisone. More commonly, such therapy achieves incomplete responses and disposes patients to a high probability of progressive renal scarring and a substantial risk of end-stage renal failure. Conventional cytotoxic drug therapy with azathioprine or cyclophosphamide reduces the likelihood of unfavourable renal outcomes, but this advantage is offset by a number of potentially serious side-effects. Intermittent pulse cyclophosphamide treatment produces the lowest risk of renal failure and appears to have a substantially reduced rate of toxicity.

狼疮性肾炎:自然史、预后和治疗
狼疮性肾炎是由一系列临床和形态学特征组成的。世界卫生组织的分类描述了狼疮性肾炎的类别,这些类别具有一些独特的特征。然而,它在评估预后和治疗指征方面的效用可以通过补充描述肾脏病理的活动性和慢性特征来增强。所有形式的狼疮性肾炎的预后在过去的几十年里已经改善了辅助医学治疗和更有效的免疫抑制方案的结果。一些活动性狼疮性肾炎患者对大剂量强的松可能有显著和完全的反应。更常见的是,这种治疗达到不完全缓解,使患者有很大可能出现进行性肾瘢痕形成和终末期肾功能衰竭的风险。传统的细胞毒性药物治疗与硫唑嘌呤或环磷酰胺减少了不良肾脏结果的可能性,但这一优势被一些潜在的严重副作用所抵消。间歇性脉冲环磷酰胺治疗产生肾功能衰竭的风险最低,似乎具有显著降低的毒性率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信